Vaccine for hypertension: Modulating the renin-angiotensin system

International Journal of Cardiology

Volumn 134, Issue 2, 2009, Pages 160-168

  Pandey, Rabindra ^a   Quan, Wu Yong ^b   Hong, Fang ^a   jie, Su Li ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Auto immune; Immunization; Virus like particle

Indexed keywords

ALISKIREN; ALUMINUM HYDROXIDE; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR VACCINE; ANGIOTENSIN I; ANGIOTENSIN I VACCINE; ANGIOTENSIN II; ATR12181; CAPTOPRIL; CYT006; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE VACCINE; PMD 2850; PMD 3117; PROTEIN C JUN; RENIN; TETANUS TOXOID; UNCLASSIFIED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIAL; COUGHING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; HALF LIFE TIME; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNIZATION; INCIDENCE; INJECTION SITE REACTION; NONHUMAN; ONCOGENE C MYC; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VIRUS LIKE AGENT;

HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; VACCINES;

EID: 64849097734     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.03.032     Document Type: Review

References (66)

1. Patricia M.K., Megan W., Kristi R., Paul M., Paul K.W., and Jiang H. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
2. Singh R.B., Suh I.L., Singh V.P., et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 14 (2000) 749-763
3. Aram V.C., M George L.B., Henry R.B., et al. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), NIH Publication. JAMA 289 (2003) 10.1001/jama.289.19.2560
4. Akiyoshi F., Keiichi S., Eriko T., Fumihiro S., Seo M.S., and Takahashi S. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268 16 (1993) 11,617-11,621 Issue of June 5
5. J.L. Lavoie, C.D. Sigmund. Mini review: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144(6):2179-2183.
6. Robert M. Carey and Helmy M. Siragy. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24(3):261-271.
7. Hiroyuki K., Masaomi N., Gabriel N.L., and Akira N. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59 (2007) 251-287
8. Takeshi S., Shinichiro N., kEIJI T., Eriko T., Toshiyuki Y., and Kenkichi I. Angiotensin II type 1a receptor deficient mice with hypotension and hyperreninemia. J Biol Chem 270 32 (1995) 18,719-18,722 Issue of August 11
9. Swafford Jr. A.N., Harrison-Bernard L.M., and Dick G.M. Knockout mice reveal that the angiotensin II type 1B receptor links to smooth muscle contraction. Am J Hypertens 20 3 (Mar 2007) 335-337
10. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 (2002) 3A-10A (suppl)
11. K.M. Baker, M.I. Chernin, S.K. Wixson, and J.F. Aceto. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. AJP-Heart Circ Physiol, Vol 259, Issue 2 H324-H332.
12. Günter B., Stephan R.H., Karin J., Daniela G., Frank M., and Eckhard P.K. Blockade of the renin angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 25 (1995) 250-259
13. Lucia M., Jurg N., Jean-Francois A., Dorette B.B., Giulio G., and Hans R.B. Blood pressure independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 31 (1998) 1324-1330
14. Yasushi S., Kazuhiro Y., Toshiaki M., Nagahiro N., Junichi Y., and Masatsugu H. Activation of matrix metalloproteinase precedes left ventricular remodeling in hypertensive heart failure rats its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
15. Brasier A.R., Recinos A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 (2002) 1257-1266
16. Ruiz-Ortega M., Lorenzo O., Rupérez M., Esteban V., Suzuki Y., and Mezzano S. Role of the renin angiotensin system in vascular diseases expanding the field. Hypertension 38 (2001) 1382-1387
17. Weir M.R., and Dzau V.J. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12 12 Pt 3 (Dec 1999) 205S-213S
18. Ascan W., Georg N., Eberhard S., Roland M., Jan Hinrich B., and Mikhail S. Increased NADH-oxidase mediated superoxide production in the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
19. Tsuyoshi O., Michael F., Wilbur L.O., Douglas E.V., and Agnes F. Modulation of plasminogen activator inhibitor-i in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51 (1997) 164-172
20. Belle E., Bauters C., Wernert N., Delcayret C., McFadden E.P., and Dupuis B. Angiotensin converting enzyme inhibition prevents proto-oncogene expression in the vascular wall after injury. J Hypertens 13 1 (January 1995) 105-112
21. Zhou D., Liang Q., He X., and Zhan C. Changes of c-fos and c-jun mRNA expression in angiotensin II-induced cardiomyocyte hypertrophy and effects of sodium tanshinone IIA sulfonate. J Huazhong Univ Sci Technolog Med Sci 28 5 (Oct 2008) 531-534
22. Ondetti M.A., Rubin B., and Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196 (1977) 441-444
23. Pool J.L., Gennari J., Goldstein R., et al. Controlled multicenter study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 3 (1987) S36-S42
24. Lancaster S.G., and Todd P.A. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35 6 (June 1988) 646-669
25. Brown N.J., and Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 97 (1998) 1411-1420
26. Wong P.C., Chiu A.T., Price W.A., et al. Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl) imidazole-5-acetic acid, sodium salt (S-8307). J Pharmacol Exp Ther 247 1 (Oct 1988) 1-7
27. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 355 (2000) 637-645
28. Meier P., Maillard M., and Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets-Cardiovasc Hematol Disord 5 (2005) 15-30
29. Wood J.M., Maibaum J., Rahuel J., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 (2003) 698-705
30. Lam S., and Choy M. Aliskiren: an oral renin inhibitor for the treatment of hypertension 2007 vol. 15(6) (November/December 2007), Lippincott Williams & Wilkins 316-323
31. Alan H. Gradman, Rishi Kad. Renin inhibition in hypertension. J Am Coll Cardiol 51 (2008) 519-528
32. Stephen B.H., Walter M., Sheila A.G., Fiona M., and Anthony F.L. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 16 (1990) 603-614
33. Wu J.N., and Berecek K.H. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 22 (1993) 139-146
34. Stevo J., Shawna D.N., Brent M.E., Michael A.W., Eric L.M., and Niko K. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
35. Skov K., Hans E., Hans E.H., Jens K.M., Stinne K., and Michael J.M. Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 50 (2007) 89-95
36. Lombard M., Pastoret P.P., and Moulin A. A brief history of vaccines and vaccination. Rev Sci Tech 26 1 (Apr 2007) 29-48
37. Behbehani A.M. The smallpox story: life and death of an old disease. Microbiol Rev 47 4 (December 1983) 455-509
38. Goldblatt H., Haas E., and Lamfrom H. Antirenin in man and animals. Trans Assoc Am Physicians 64 (1951) 122
39. Deodhar S.D., Haas E., and Goldblatt H. Production of antirenin to homologous renin and its effect on experimental renal hypertension. J Exp Med 139 (1964) 425-435
40. Wakerlin G.E. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 17 (1958) 653-657
41. Deodhar S.D., Haas E., and Goldblatt H. induced changes in the antigenicity of renin and the production of antirenin to homologous renin to human renin. Can Med Assoc 90 3 (Jan. 25 1964)
42. Michel J.B., Guettier C., Reade R., et al. Immunologic approaches to blockade of the renin angiotensin system: a review. Am Heart J 117 (1989) 756-767
43. Michel J.B., Guettier C., Philippe M., Galen F.X., Corvol P., and Menard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 84 (1987) 4346-4350
44. Michel J.B., Sayah S., Guettier C., et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 81 (1990) 1899-1910
45. Johnston C.I., Hutchinson J.S., and Mendelsohn F.A. Biological significance of renin-angiotensin immunization. Circ Res 26 suppl II (1970) II-215-222
46. Graham J.M., William J.L., Vincenzo R., Graham W.B., and Stanley P. Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res XXVII (1970)
47. Oates H.F., Stokes G.S., Storey B.G., Glover R.G., and Snow B.F. Renal hypertension in rats immunized against angiotensin I and angiotensin II. J Exp Med 139 (1974) 239-248
48. Reade R., Michel J.B., Carelli C., et al. Immunization of spontaneously hypertensive rats against angiotensin 1. Arch Mal Coeur Vaiss 82 (1989) 1323-1328
49. Smits J., Auton T., Sharp J., Downham M., Glover J., and Janssen B. Anti-hypertensive properties of angiotensin immunotherapeutic in spontaneous hypertension in rats. FASEB J 13 (1999) A48
50. Gardiner S.M., Auton T.R., Downham M.R., et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 129 (2000) 1178-1182
51. M.P. Schutze, C. Leclerc, M. Jolivet, F. Audiber and L. Chedid. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol, Vol 135, Issue 4 2319-2322.
52. Downham M.R., Auton T.R., Rosul A., et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 56 (2003) 505-512
53. Brown M.J., Coltart J., Gunewardena K., et al. Randomized double blind placebo controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 107 (2004) 167-173
54. Linda Brookes. New antihypertensive therapies and old hypertensive risks? Medscape cardiology Posted: 04/17/2008 url: http://www.medscape.com/viewarticle/572933.
55. Zhu F., Liao Y.H., Li L.D., et al. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR 12181 in spontaneously hypertensive rats. Cell Mol Immunol 3 (2006) 107-114
56. Zhu F., Liao Y.-H., Li L., et al. Abstract 2753: observation of long-term efficacy and safety of an ATR12181 vaccine against hypertension in SHR. Circulation 114 (Oct 2006) II_575
57. Maurer P., Jennings G.T., Willers J., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 35 (2005) 2031-2040
58. Gary T. Jennings, Martin F. Bachmann. The coming of age of virus-like particle vaccines. Biol Chem Volume: 389 Issue: 5 Pages: 521-536.
59. Ambuhl P.M., Tissot A.C., Fulurija A., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase 1 safety and immunogenicity. J Hypertens 25 (2007) 63-72
60. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., and Ignatenko S. Effect of immunizations against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study. Lancet 371 9615 (2008) 821-827
61. Muller J.E., Tofler G.H., and Stone P.H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79 (1989) 733-743
62. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 1 (2002) 3
63. Samuelsson O, Hans H. Vaccination against high blood pressure: a new strategy. www.thelancet.com Vol 371 March 8, 2008.
64. Johnston C.I. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 23 (1994) 258-268
65. Michael J.B. Renin-angiotensin vaccine: old story, new project efficacy versus safety. Clin Sci 107 (2004) 145-147
66. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150